NVDA
NVIDIA
-- 139.400 INTC
Intel
-- 27.390 SMCI
Super Micro Computer
-- 55.800 TSLA
Tesla
-- 354.110 GRAB
Grab Holdings
-- 5.300 
NEWS
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed (NASDAQ: CRVO) announced that its oral drug neflamapimod received Orphan Drug Designation from the FDA for treating frontotemporal dementia (FTD).
CervoMed (NASDAQ: CRVO) announced that its oral drug neflamapimod received Orphan Drug Designation from the FDA for treating frontotemporal dementia (FTD).
The designation applies to therapies for rare diseases affecting fewer than 200,000 people in the US and provides benefits including tax credits, development assistance, and seven years of marketing exclusivity.
The company is preparing for a Phase 3 trial in dementia with Lewy bodies (DLB) in mid-2025 and expects topline data from the RewinD-LB Phase 2b trial in December 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8245
Followers
52
Following
94K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call